• English

    Google Translate Disclaimer

    The Maryland Department of Information Technology (“DoIT”) offers translations of the content through Google Translate. Because Google Translate is an external website, DoIT does not control the quality or accuracy of translated content. All DoIT content is filtered through Google Translate which may result in unexpected and unpredictable degradation of portions of text, images and the general appearance on translated pages. Google Translate may maintain unique privacy and use policies. These policies are not controlled by DoIT and are not associated with DoIT’s privacy and use policies. After selecting a translation option, users will be notified that they are leaving DoIT’s website. Users should consult the original English content on DoIT’s website if there are any questions about the translated content.

    DoIT uses Google Translate to provide language translations of its content. Google Translate is a free, automated service that relies on data and technology to provide its translations. The Google Translate feature is provided for informational purposes only. Translations cannot be guaranteed as exact or without the inclusion of incorrect or inappropriate language. Google Translate is a third-party service and site users will be leaving DoIT to utilize translated content. As such, DoIT does not guarantee and does not accept responsibility for, the accuracy, reliability, or performance of this service nor the limitations provided by this service, such as the inability to translate specific files like PDFs and graphics (e.g. .jpgs, .gifs, etc.).

    DoIT provides Google Translate as an online tool for its users, but DoIT does not directly endorse the website or imply that it is the only solution available to users. All site visitors may choose to use alternate tools for their translation needs. Any individuals or parties that use DoIT content in translated form, whether by Google Translate or by any other translation services, do so at their own risk. DoIT is not liable for any loss or damages arising out of, or issues related to, the use of or reliance on translated content. DoIT assumes no liability for any site visitor’s activities in connection with use of the Google Translate functionality or content.

    The Google Translate service is a means by which DoIT offers translations of content and is meant solely for the convenience of non-English speaking users of the website. The translated content is provided directly and dynamically by Google; DoIT has no direct control over the translated content as it appears using this tool. Therefore, in all contexts, the English content, as directly provided by DoIT is to be held authoritative.

    ​PDMP Use Mandate Information


    The PDMP Use Mandate applies to both CDS Prescribers and Pharmacists.  See below for information specific to each profession.

    Effective July 1, 2018, a Prescription Drug Monitoring Program (PDMP) use mandate for providers prescribing controlled dangerous substances (CDS) medications and pharmacists goes into effect.  The full text of the use mandate can be found in Health General-Article § 21-2A-04.2​. 

    The requirements and exemptions of this mandate are summarized below. 

    Mandatory Use for CDS Prescribers:  Prescribers include the following practitioners with CDS prescriptive authority:  physicians, physician assistants, dentists, podiatrists, nurse practitioners, and advanced practice nurse midwives.  Prescribers must query and assess PDMP data (through the CRISP portal or integration within the Electronic Health Record (EHR), where available):

    • ​Before beginning a new course of treatment with opioids or benzodiazepines 
    • When a course of treatment extends beyond 90 days. In this case, prescribers must query again at least every  90 days thereafter before prescribing or dispensing opioids or benzodiazepines
    • Must view at least the last 4 months of data ( This will always be available within a PDMP data view.) 
    • A prescriber delegate may pull the PDMP data, but the prescriber remains responsible for assessing the data prior to making a prescribing decision.

    Exceptions to this mandate: A prescriber is NOT REQUIRED to request PDMP data if the opioid or benzodiazepine is prescribed or dispensed to an individual:

    • For a period of 3 days or less (
    • For cancer treatment or cancer-related pain
    • For a patient who is:
      • Receiving treatment in an inpatient unit of a hospital
      • Part of a general hospice program*
      • Diagnosed with a terminal illness *
      • Residing in a nursing home, long-term care, developmental disability, or assisted living facility
    • To treat or prevent acute pain for a period of 14 days or less (
      • Surgical procedure*
      • Bone Fracture
      • Significant trauma*
      • Childbirth

     * See specific FAQs for definitions of these terms

     Mailing to Prescribers May/June 2018

    Mandatory Use for Pharmacists:  Pharmacists must query and assess the PDMP data when they suspect any CDS prescription is being filled for something other than treatment of an existing medical diagnosis, essentially a restatement of the corresponding responsibility under federal regulations.
    Effective adoption of PDMP as a clinical decision support tool both under the use mandate, and as recommended by the Centers for Disease Control and Prevention (CDC), the President’s Opioid Commission on Combating Drug Addiction and the Opioid Crisis, and the Maryland Heroin and Opioid Emergency Task Force relies on integrating PDMP data access into the realities of a put in place to assist providers are:
    1. Use of Delegates, who can access the PDMP on behalf of a prescriber or pharmacist and provide that PDMP data report to the provider for a prescribing or dispensing decision
    2. Integrating PDMP access into an EHR, which is available in many hospital system settings across the state​

    Mailing to Pharmacists May/June 2018